ATE400573T1 - 1h-imidazochinolinderivate als proteinkinaseinhibitoren - Google Patents

1h-imidazochinolinderivate als proteinkinaseinhibitoren

Info

Publication number
ATE400573T1
ATE400573T1 AT04798017T AT04798017T ATE400573T1 AT E400573 T1 ATE400573 T1 AT E400573T1 AT 04798017 T AT04798017 T AT 04798017T AT 04798017 T AT04798017 T AT 04798017T AT E400573 T1 ATE400573 T1 AT E400573T1
Authority
AT
Austria
Prior art keywords
protein kinase
imidazocinoline
derivatives
kinase inhibitors
imidazoquinolines
Prior art date
Application number
AT04798017T
Other languages
English (en)
Inventor
Hans-Georg Capraro
Giorgio Caravatti
Pascal Furet
Carlos Garcia-Echeverria
Patricia Imbach
Frederic Stauffer
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE400573T1 publication Critical patent/ATE400573T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT04798017T 2003-11-21 2004-11-19 1h-imidazochinolinderivate als proteinkinaseinhibitoren ATE400573T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52422903P 2003-11-21 2003-11-21

Publications (1)

Publication Number Publication Date
ATE400573T1 true ATE400573T1 (de) 2008-07-15

Family

ID=34652264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04798017T ATE400573T1 (de) 2003-11-21 2004-11-19 1h-imidazochinolinderivate als proteinkinaseinhibitoren

Country Status (16)

Country Link
US (1) US20080262021A1 (de)
EP (1) EP1687305B1 (de)
JP (1) JP2007511575A (de)
KR (1) KR20060117329A (de)
CN (1) CN1902200A (de)
AT (1) ATE400573T1 (de)
AU (1) AU2004295061B2 (de)
BR (1) BRPI0416801A (de)
CA (1) CA2546117A1 (de)
DE (1) DE602004014969D1 (de)
ES (1) ES2308272T3 (de)
MX (1) MXPA06005702A (de)
PL (1) PL1687305T3 (de)
PT (1) PT1687305E (de)
RU (1) RU2006121646A (de)
WO (1) WO2005054237A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538057A (ja) 2002-06-07 2005-12-15 スリーエム イノベイティブ プロパティズ カンパニー エーテル置換イミダゾピリジン
EP1590348A1 (de) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl-substituierte imidazochinoline
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
EP1673087B1 (de) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy-substituierte imidazochinoline
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
KR101494056B1 (ko) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
JP5209312B2 (ja) 2004-09-02 2013-06-12 スリーエム イノベイティブ プロパティズ カンパニー １−アルコキシ１ｈ−イミダゾ環系および方法
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
EP1846405A2 (de) 2005-02-11 2007-10-24 3M Innovative Properties Company Oxim- und hydroxylaminsubstituierte imidazo-4,5-c-ringverbindungen und verfahren
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1851218A2 (de) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkylsubstituierte imidazochinolinverbindungen und verfahren
AU2006216686A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
AU2006223634A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CA2602590A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2602683A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006287270A1 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EP1988896A4 (de) 2006-02-22 2011-07-27 3M Innovative Properties Co Konjugate zur modifizierung von immunreaktionen
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2447359B1 (de) 2006-04-14 2015-11-04 Cell Signaling Technology, Inc. Gendefekte und mutierte ALK-Kinase in festen menschlichen Tumoren
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
KR20090080530A (ko) 2006-11-20 2009-07-24 노파르티스 아게 2-메틸-2-[4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조[4,5-ｃ]퀴놀린-1-일)-페닐]-프로피오니트릴의 염 및 결정 형태
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
RU2478387C2 (ru) * 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
MX2010007699A (es) * 2008-01-15 2010-08-04 Meda Ab Tratamiento de enfermedades del colon o prevencion de carcinoma colorrectal con derivados de imidazoquinolina.
EP2474323A3 (de) * 2008-03-26 2012-10-10 Novartis AG Imidazoquinolin- und Pyrimidinderivate als starke Modulatoren von VEGF-gesteuerten angiogenetischen Prozessen
BRPI1008325A2 (pt) 2009-02-11 2020-08-25 Merck Patent Gmbh carboxamidas azaeterocíclicas de amino
GEP20156267B (en) 2009-06-04 2015-04-14 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
BR112012002336A2 (pt) 2009-08-07 2016-05-31 Merck Patent Gmbh compostos aza-heterocíclicos
JP5863058B2 (ja) 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １Ｈ−イミダゾ［４，５−ｃ］キノリン
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
TW201204725A (en) * 2010-07-16 2012-02-01 Piramal Lifesciences Ltd Substituted imidazoquinoline derivatives as kinase inhibitors
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
BR112013002212A2 (pt) 2010-07-29 2017-09-26 Merck Patent Gmbh carboxamidas aza-heterocíclicas de aminas cíclicas
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
LT2606047T (lt) 2010-08-17 2017-04-10 3M Innovative Properties Company Imuninio atsako modifikatoriaus junginio lipidizuotos kompozicijos, sudėtys ir būdai
MX355836B (es) 2010-08-20 2018-05-02 Chugai Pharmaceutical Co Ltd Composicion que comprende compuestos tetraciclicos.
US9181264B2 (en) 2010-09-16 2015-11-10 Hutchison Medipharma Limited Fused heteroaryls and their uses
CN103124731B (zh) * 2010-09-16 2016-01-20 和记黄埔医药（上海）有限公司 稠合的杂芳基化合物及其应用
US20130225524A1 (en) * 2010-11-05 2013-08-29 Deping Chai Chemical Compounds
WO2012069146A1 (en) 2010-11-24 2012-05-31 Merck Patent Gmbh Quinazoline carboxamide azetidines
KR20140010009A (ko) * 2010-12-03 2014-01-23 노파르티스 아게 제약 조성물
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
EP2717919B1 (de) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunktionale linker mit polyethylenglykolsegmenten und daraus hergestellte immunantwort-modifizierende konjugate
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
SI2755965T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Novi imidazolni amidi kot modulatorji kinazne aktivnosti
SG2014009260A (en) 2011-09-12 2014-09-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
CN103012398B (zh) * 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
ES2527188T3 (es) * 2011-09-26 2015-01-21 Sanofi Derivados de pirazolquinolinona, su preparación y su uso terapéutico
JP6096205B2 (ja) 2011-11-01 2017-03-15 モッドジーン リミテッド ライアビリティ カンパニーＭｏｄｇｅｎｅ，Ｌｌｃ 低減されたタンパク質キナーゼ阻害を呈するイマチニブ誘導体の使用
BR112014015327B1 (pt) 2011-12-22 2020-10-27 Merck Patent Gmbh composto, seu uso e composição farmacêutica
US10668075B2 (en) 2012-09-25 2020-06-02 Chugai Seiyaku Kabushiki Kaisha RET inhibitor
JP6386467B2 (ja) 2012-11-16 2018-09-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規複素環式誘導体
ES2807539T3 (es) 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
WO2014085528A1 (en) 2012-11-29 2014-06-05 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
WO2014121654A1 (zh) * 2013-02-05 2014-08-14 山东轩竹医药科技有限公司 四并环激酶抑制剂
SG11201505999VA (en) 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
WO2014177915A1 (en) * 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
WO2015022663A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022664A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AU2015240094B2 (en) 2014-04-03 2020-07-30 Merck Patent Gmbh Combinations of cancer therapeutics
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
EP3135671B1 (de) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Neuartiger kristall einer tetracyclischen verbindung
NO2714752T3 (de) 2014-05-08 2018-04-21
TWI831347B (zh) 2014-08-08 2024-02-01 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
JP6741596B2 (ja) 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US10988472B2 (en) 2016-10-13 2021-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for blocking transmission of malarial parasite
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019040491A1 (en) 2017-08-22 2019-02-28 Dynavax Technologies Corporation MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
EP3728255B1 (de) 2017-12-20 2022-01-26 3M Innovative Properties Company Amid-substituierte imidazo[4,5-c]chinolin-verbindungen mit verzweigtkettenverbindungsgruppe zur verwendung als immunreaktionsmodifikator
EP3740490A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrazol[3,4-d]pyridin-verbindungen als ret-kinasehemmer
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrrolo[2,3-d]pyrimidinverbindungen als ret-kinase-inhibitoren
CN112384223B (zh) 2018-06-29 2024-08-27 中外制药株式会社 含有难溶性碱性药剂的药物组合物
WO2020050241A1 (ja) 2018-09-04 2020-03-12 中外製薬株式会社 ４環性化合物の製造方法
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
CN118619944A (zh) 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
JP2023551408A (ja) 2020-11-16 2023-12-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング がん処置のためのキナーゼインヒビター組み合わせ
CN117800964A (zh) * 2022-09-30 2024-04-02 四川大学 PI3K/m-TOR抑制剂及其应用
CN121219289A (zh) * 2024-04-26 2025-12-26 浙江师范大学 吡啶或吡嗪并三环化合物及其药用组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323388A (en) * 1980-03-10 1982-04-06 Ciba-Geigy Corporation Cyanoalkyl-phenylureas having selective herbicidal activity
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1256582A1 (de) * 2000-02-09 2002-11-13 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridin-derivate
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
EP1590348A1 (de) * 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl-substituierte imidazochinoline

Also Published As

Publication number Publication date
RU2006121646A (ru) 2008-01-10
PL1687305T3 (pl) 2008-12-31
WO2005054237A1 (en) 2005-06-16
CA2546117A1 (en) 2005-06-16
EP1687305B1 (de) 2008-07-09
CN1902200A (zh) 2007-01-24
MXPA06005702A (es) 2006-08-17
EP1687305A1 (de) 2006-08-09
BRPI0416801A (pt) 2007-01-09
ES2308272T3 (es) 2008-12-01
PT1687305E (pt) 2008-10-17
AU2004295061A1 (en) 2005-06-16
AU2004295061B2 (en) 2008-11-20
KR20060117329A (ko) 2006-11-16
DE602004014969D1 (de) 2008-08-21
JP2007511575A (ja) 2007-05-10
US20080262021A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
DE602004014969D1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
NO20055496D0 (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
CY1108246T1 (el) ΠΑΡΑΓΩΓΑ 1Η-ΘΕΙΕΝΟ[2,3-c] ΠΥΡΑΖΟΛΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
EA200600833A1 (ru) Тиазолидиноны, их получение и применение как фармацевтических агентов
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
DE60316410D1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
DE50212538D1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzoäcüfluoren-6-carbonsäurederivate als nmda-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1687305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee